openPR Logo
Press release

OX-40 Receptor Agonist Therapeutics Analysis by Top Key Players - Pfizer, MedImmune, Agenus, GlaxoSmithKline plc

11-14-2018 09:18 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

OX-40 Receptor Agonist Therapeutics Analysis by Top Key Players

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Download report sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

Browse report at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

OX-40 Receptor Agonist Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
347 5th Ave. #1402- 210
New York City, NY 10016 United States
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OX-40 Receptor Agonist Therapeutics Analysis by Top Key Players - Pfizer, MedImmune, Agenus, GlaxoSmithKline plc here

News-ID: 1371078 • Views:

More Releases from P&S Intelligence

Remote Access Provided by Cloud Category Fuels Call Center AI Market
Remote Access Provided by Cloud Category Fuels Call Center AI Market
In 2021, the call center AI market generated sales worth $1,982.9 million, and it is expected to contribute $12,910.6 million in 2030, progressing at a rate of 23.1% from 2021 to 2030, ascribed to the growing up requirements for improved data analytics to manage customer inquiries with the real-time response to improve customer engagement through social media. In order to pace up the 4th industrial revolution, businesses across various industries
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Market
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Marke …
The total value of the customer engagement solutions market was $18,186.8 million in 2021, and it will rise at a growth rate of above 10% in the near future, to reach $43,398.9 million by 2030. The major reasons behind the growth of this industry are growing usage of such solutions in serval industries like healthcare, telecommunications, BFSI and FMCG. North America will grow the fastest with a rate of 10.5% in
Reduced Operational Cost of Energy Efficient Motors Propels Motion Control Market
Reduced Operational Cost of Energy Efficient Motors Propels Motion Control Marke …
The motion control market generated a revenue of $14,887.5 million in 2021, and it is expected to contribute $23,286.4 million in 2030, progressing at a rate of 5.1% from 2021 to 2030, ascribed to the rising demand for industrial robots and integration of components with the motion control systems for convenient use. Moreover, the evolving motion control standards and protocols propel the market, for example, the OPC UA TSN protocol controls
North America, the Largest Revenue Producer in Public Safety and Security Market
North America, the Largest Revenue Producer in Public Safety and Security Market
The size of the public safety and security market was at $411 billion in the year 2021, which will reach over $1,115 billion by the year 2030, advancing at a growth rate of around 12% in the years to come. This is largely ascribed to the rising application of innovative technologies in smart cities, increasing crime rates, the increasing cases of disastrous accidents, and the growing count of terrorist activities

All 5 Releases


More Releases for Receptor

DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologo …
DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Pipeline Insight, 2020 report by comprehensive insights of present scenario and growth prospects across DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action,
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Gh …
"The Report Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfa …
ReportsWorldwide has announced the addition of a new report title Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfa …
Market Research Hub (MRH) added a new research report to its vast database titled “Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Pipeline Review, H2 2017” Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.  Request
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Recept …
Market Research Hub (MRH) has added a new report titled “Calcitonin Gene Related Peptide Type 1 Receptor, Pharmaceutical Pipeline Research Report” to its vast data repository. Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Rece …
"Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Directs, Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016, provides in depth analysis on Transient Receptor Potential Cation